Marianne K Møller, Institut for Klinisk Medicin - Medicinsk Endokrinologisk Afd., MEA, NBG
,
Henrik F. Thomsen
,
Christina Jørgensen, Novo Nordisk A/S, Denmark
Jørgen S Smedegaard, Novo Nordisk A/S, Denmark
Torsten Lauritzen, Denmark
Jens S Christiansen, Denmark
The Department of Endocrinology and Diabetes
Department of Pharmacology
Department of Clinical Epidemiology
Institute of General Medical Practice
Basal continuous subcutaneous insulin infusion (CSII) therapy at a fixed rate may effectively improve glycemic control in patients with type 2 diabetes when oral antidiabetic treatment fails. Regimens of simple constant subcutaneous delivery of insulin may provide theoretical advantages in type 2 diabetes.